Tempus AI (TEM) Analysis
Despite ongoing business improvements and product expansion, Tempus AI’s efforts are plagued by data privacy lawsuits, a short report from 2025, and a risk of client concentration.
What does Tempus AI do?
For those who’ve been with us for a while…we first initiated coverage on Tempus AI in late 2024, and it has since been on a wild ride. The “AI” in its name made it an obvious bet on the AI boom, and unlike other AI companies that are riding the waive without real fundamentals, Tempus AI is highly relevant in its industry.
Tempus operates in fields such as healthcare, genetic testing, clinical data, and artificial intelligence. The company collects and organizes large amounts of medical information (like genomic testing results, physician notes, imaging data, treatment histories, clinical outcomes) and uses that data to help doctors and pharmaceutical companies make better decisions.
The business of organizing and commercializing data is booming as companies race to prepare their information for artificial intelligence. The global enterprise data management market was valued at roughly $123 billion in 2025 and is projected to reach approximately $320 billion by 2033, representing annualized growth of nearly 13%. That puts Tempus in a position to take advantage of this boom if it holds out, but it has to overcome the current headwinds.
What’s Holding Tempus AI back
A shareholder lawsuit filed in 2025 accused Tempus and certain executives of misleading investors about the strength of the company’s AI capabilities and business fundamentals (so its very name backfired on it). These claims have not been proven, but they add to the company’s legal overhang.
Moreover, the business itself hasn’t been growing as rapidly as investors hoped…at least not compared to some of the bigger names involved in AI. Tempus quarterly pace of revenue growth has declined from 80%+ growth on average, to just 36% last quarter. And net income has suffered for three consecutive quarters, a problem that continues to weigh on profit outlook and the overall business.
Hyper Stocks Summary
Tempus AI is one of the more legitimate AI related companies in the public market. It has a real business, real revenue growth, major healthcare partnerships, a valuable database, and a clear opportunity to improve how diseases are diagnosed and treated.
However, being relevant does not automatically make the stock attractive at every valuation. The company remains a high risk growth story. Its future depends on turning diagnostics generated data into a scalable, higher margin platform while resolving legal disputes, reducing client concentration, and reaching sustainable profitability.
Disclaimer: This article is for informational and educational purposes only and does not constitute financial advice. Investing involves risk, including the possible loss of capital. Always conduct your own research or consult with a licensed financial advisor before making investment decisions.
Hyper Stocks and its contributors may hold positions in some of the securities or assets mentioned above. These positions are subject to change without notice. Any opinions expressed reflect current views at the time of writing and are not guarantees of future performance. Past performance does not guarantee future results.